A critical role of COX-2 in the progression of neointimal formation after wire injury in mice

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 5, 2009, Pages 505-511

  Ogawa, Masahito ^a,b   Suzuki, Jun Ichi ^a,b   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Isobe, Mitsuaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Arterial injury; COX 2; Intimal hyperplasia; Macrophages

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 6; MELOXICAM; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMORAL ARTERY; GENE EXPRESSION; HISTOPATHOLOGY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ARTERIOSCLEROSIS; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; FEMORAL ARTERY; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER; STRESS, MECHANICAL; THIAZINES; THIAZOLES; TUNICA INTIMA;

EID: 67649631527     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902901120     Document Type: Article

References (28)

1. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;73:710-7
2. Holmes DR. In-stent restenosis. Rev Cardiovasc Med 2001;2:115-9
3. Danzi GB, Sesana M, Capuano C, et al. Restenosis after NIR stent implantation. Minerva Cardioangiol 2002;50:455-62
4. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72
5. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95:40S-44S
6. Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993;307:361-8
7. Jones DA, Carlton DP, Mcintyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54
8. Dubois RN, Awad J, Morrow J, et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 1994;93:493-8
9. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Expert Opin Pharmacother 2001;2:1859-76
10. Kiefer W, Dannhardt G. COX-2 inhibition and the control of pain. Curr Opin Investig Drugs 2002;3:1348-58
11. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003;63:33-45
12. Koki A, Khan NK, Woerner BM, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 2002;507:177-84
13. Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 2002;11:1749-64
14. Suzuki J, Ogawa M, Futamatsu H, et al. A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006;40:688-95
15. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993;73:792-6
16. Inagaki H, Suzuki J, Ogawa M, et al. Ultrasound-microbubble-mediated NF-κB decoy transfection attenuates neointimal formation after arterial injury in mice. J Vasc Res 2006;43:12-8
17. Suzuki J, Izawa A, Isobe M. Anti-vascular cell adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies inhibit neointimal hyperplasia in the murine model of arterial injury. Acta Cardiol 2004;59:147-52
18. Koo BK, Kim YS, Park KW, et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 2007;370:567-74
19. Saito T, Rodger IW, Hu F, et al. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 2004;37:71-7
20. Schober A, Manka D, von Hundelshausen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002;106:1523-9
21. Usui M, Egashira K, Ohtani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. Faseb J 2002;16:1838-40
22. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002;90:1167-72
23. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9
24. Shackelford RE, Alford PB, Xue Y, et al. Aspirin inhibits tumor necrosis factor-α gene expression in murine tissue macrophages. Mol Pharmacol 1997;52:421-9
25. Yasukawa K, Hirano T, Watanabe Y, et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987;6:2939-45
26. Tian B, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 2003;58:95-130
27. Wang K, Tarakji K, Zhou Z, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005;45:61-7
28. Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004;110:301-8